Next-Generation BTK Inhibitor Among New Filings At EMA

The European Medicines Agency has begun reviewing a new batch of EU marketing authorization applications.

Wooden blocks with the word Review. Customer review concept. Reviewing, auditing, reviewer. Service rating. Feedback.
New medicines have been filed for review by the EMA • Source: Alamy

Eli Lilly’s next-generation Bruton's tyrosine kinase (BTK) inhibitor, pirtobrutinib, is among the new drugs that the European Medicines Agency has begun reviewing for potential pan-EU marketing approval.

Pirtobrutinib, which Lilly has filed with the EMA for treating mantle cell lymphoma, is an investigational highly selective, non-covalent (reversible)...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet